“a strong trend”

In the subset MSSOpoly, differences, most of which were not statistically significant, could be obtained in onset symptoms and symptoms at the last visit, with a strong trend of a higher rate of walking impairments in MSSOpoly (68%) compared to MSS- (50%, p = 0.051). 58% of MSSOpoly were working at the last reported visit compared to 67% in MSS- ( p = 0.4).

Post hoc t-tests confirmed significant differences between female domestic guinea pigs and female wild cavies (t(24) = -2.25, p = 0.034) and revealed a strong trend for the difference between male domestic guinea pigs and male wild cavies (t(23) = -2.06, p = 0.051).

Interaction effects between ACE and A3B I/D polymorphisms on clinical characteristics No significant differences were found between the clinical characteristics of the carriers of both the ACE D and A3B I alleles and the remainder among the males or females of the 1199 adults, although there was a strong trend for aspartate aminotransferase in females (P = 0.051; Table 3 and Table 4 ).

We also observed a strong trend for increased MnSOD abundance in exercise-trained skeletal muscle of healthy humans ( p = 0.051; n = 6).

In HBsAg-positive DLBCL group (Table 2 ), there was a strong trend that the response in the R-CHOP group was better than that in the CHOP group with a higher rate of complete response (57.6% vs 22.9%, p = 0.051).

In the ON-TIME 2 Trial, the patients who received high-dose bolus Tirofiban (25 mcg/kg) before primary PCI exhibited a strong trend toward a decrease in mortality (2.2 % vs. 4.1 %, P = 0.051), which was maintained during one year's follow-up (3.7 % vs. 5.8 %, p value = 0.08) ( 30 ).

In the context of a more complex routine procedure, such as robot-assisted partial nephrectomy, there was a significant association [ 34 ] or a strong trend ( p = 0.051) [ 35 ] for an impact of the level of experience of the bedside assistant on the operative duration.

Targeted t tests indicated elevated p53 protein expression in the SCI groups compared to the Sham group at 2 weeks ( p = .0152) and 2 months ( p = .0317), with a strong trend for elevated expression at 1 month ( p = .0510).

There was a strong trend towards an increase in variant coefficient when comparing R6/2 (vehicle) mice with WT littermates ( p = 0.051) (Fig. 4f ).

In addition, LN-positive patients had a strong trend to significantly higher IL-23 (p=0.051) and TNF-a (p<0.08) expression.

Although not significant, there was a strong trend towards better 5-year bRFS rates with higher radiotherapy doses (52%, 83%, and 76% for 74R72, 76R74, and 78R76, resp., P = 0.051) ( Figure 1 ).

When Mamu-A*01 animals were included, the dmLT group was not significantly protected, although there was a strong trend ( p = 0.051; Supplementary Figure S7B ), and the alum group was not protected ( p = 0.49; Supplementary Figure S7B ).

There was a strong trend toward a decrease in mortality (2.2% vs. 4.1%, p = 0.051) in patients who were randomized to tirofiban pre-treatment, which was maintained during the 1-year follow-up (3.7% vs. 5.8%, p = 0.08).

This effect was specific to the initial 7 days of extinction training, when the sessions were preceded by injections, as shown by a strong trend toward a significant treatment group × training day interaction ( F 12, 90 = 1.8, P = 0.051) in Days 1–7, but no such trends or significant interactions in Days 10–13.

A strong trend toward increased regional frontocentral theta ( P =0.051) was observed in AN patients.

There was a significant main effect of test type (name detection/segregation detection: beta = −2.82, CI −4.24 to −1.41, p < 0.001) and a strong trend to a main effect of group (beta = −0.88, CI −1.77 to 0.003, p = 0.051).

There was a strong trend towards higher ICU mortality (38.2% vs. 51.4%; p = 0.051) and a significantly worse outcome after one year (51.4% vs. 66.0%; p = 0.031).

Cox proportional hazard model showed that only surgery was an independent prognostic factor for survival ( P = 0.047), while tumor size showed a strong trend for statistical significance ( P = 0.051).

2%, P < 0.001), with a strong trend toward improved OS in patients treated with T-VEC (23.3 vs. 18.9 months, P = 0.051).

The combination of budesonide and surfactant mixed at the bedside decreased mRNA for IL-6 and MCP-1 and had a strong trend for a decrease in IL-β ( p = 0.051).

In this way, high mRNA expression of AR was associated with significantly improved CSS ( p = 0.020) and OS (0.015) and showed a strong trend towards longer RFS ( p = 0.051; Table 3 ; Figure 1 ).

Concerning the gray matter preservation ( Figure 2 A), a significant difference was found between the group 3 × 1.5 M and the control ( p < 0.05), and a strong trend was observed when compared to the group of 0.5 M ( p = 0.051).

Furthermore, there was a strong trend towards significance when comparing the frequency of LN in patients with different genotypes of rs117026326 or rs73366469 ( P = .051, .062, respectively).

Although this result had a strong trend towards statistical significance (p = 0.051, Figure 1 , Table 1 ), this observation was not significant after adjusting for patient’s body weight (p = 0.11).

The CTVHR D98 doses showed a strong trend in favor of the MRI-based technique (6.16 ± 0.59 Gy, vs. 5.72 ± 0.95 Gy, p = 0.051).